Suppr超能文献

使用完整和胶带剥离的人体皮肤对阿昔洛韦产品经皮吸收的体外评估。

In vitro evaluation of percutaneous absorption of an acyclovir product using intact and tape-stripped human skin.

作者信息

Qureshi S A, Jiang M, Midha K K, Skelly J P

机构信息

Therapeutic Products Directorate vertical line(PL#2202C1), Health Canada, Ottawa, Ontario, Canada.

出版信息

J Pharm Pharm Sci. 1998 Sep-Dec;1(3):102-7.

Abstract

PURPOSE

To evaluate the use of a flow-through diffusion cell system to assess the absorption and penetration characteristics of drug (acyclovir) products.

METHODS

In vitro studies were performed to assess the absorption/penetration of acyclovir using a flow-through diffusion cell system with human skin sections obtained from 19 healthy women following mammoplasty. The skin sections, 200-400 microm thick, were prepared using a dermatome. Acyclovir ointment (approximately 10 mg) spiked with (3)H-labelled acyclovir was applied onto the stratum corneum/epidermis side. The skin sections were continually perfused on the dermis side with sterilized culture medium, Buffered Hanks' Balanced Salt Solution, saturated with a CO(2)/O(2) (5/95%).

RESULTS

After 24 hours, the percentages of acyclovir-derived radioactivity (based on dose applied) in different components were as follows: stratum corneum (SC), 0.20+0.28; viable skin (VS), 0.40+0.38; effluent fluid (EF), 0.25+0.53. A second set of experiments was performed using tape stripped (10X) skin sections. Levels of acyclovir-derived radioactivity were VS, 1.21+1.43 and EF, 2.65+2.61, which were threefold higher (p < 0.05) for VS and elevenfold higher (p < 0.05) for EF compared to the results obtained with the intact skin sections.

CONCLUSIONS

The SC is the main barrier layer for the penetration of acyclovir through human skin. The use of the flow-through diffusion cell system provides an appropriate in vitro model to assess the absorption/penetration of acyclovir through human skin layers and therefore can potentially be used for dermal formulation characterization and development.

摘要

目的

评估流通扩散池系统用于评估药物(阿昔洛韦)产品的吸收和渗透特性。

方法

进行体外研究,使用流通扩散池系统,以从19名接受乳房成形术的健康女性获取的人体皮肤切片评估阿昔洛韦的吸收/渗透情况。使用皮肤切片机制作厚度为200 - 400微米的皮肤切片。将掺入(3)H标记阿昔洛韦的阿昔洛韦软膏(约10毫克)涂抹于角质层/表皮一侧。在真皮一侧用含有CO(2)/O(2)(5/95%)的灭菌培养基(缓冲汉克斯平衡盐溶液)持续灌注皮肤切片。

结果

24小时后,不同组分中阿昔洛韦衍生放射性(基于给药剂量)的百分比情况如下:角质层(SC),0.20 + 0.28;活皮肤(VS),0.40 + 0.38;流出液(EF),0.25 + 0.53。使用胶带剥离(10次)的皮肤切片进行了第二组实验。阿昔洛韦衍生放射性水平在VS中为1.21 + 1.43,在EF中为2.65 + 2.61,与完整皮肤切片的结果相比,VS高出三倍(p < 0.05),EF高出十一倍(p < 0.05)。

结论

角质层是阿昔洛韦透过人体皮肤的主要屏障层。流通扩散池系统的使用提供了一个合适的体外模型,以评估阿昔洛韦透过人体皮肤层的吸收/渗透情况,因此有可能用于皮肤制剂的特性表征和开发。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验